AstaZeneca seeks to show strength against Pfizer with forecast
AstraZeneca, the target of a takeover bid of more than $100 billion by Pfizer, forecast long-term sales growth as it seeks to convince investors that it can succeed as a standalone drugmaker.
AstraZeneca, the target of a takeover bid of more than $100 billion by Pfizer, forecast long-term sales growth as it seeks to convince investors that it can succeed as a standalone drugmaker.
AstraZeneca will have more than $45 billion in yearly revenue by 2023, following “strong and consistent” sales growth starting in 2017, the London-based company said today in a statement. Operating leverage will probably “result in core earnings growth in excess of revenue growth during...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month, €19.99 Monthly thereafter
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
